Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Restructuring Costs (2019)

Historic Restructuring Costs for Seres Therapeutics (MCRB) over the last 1 years, with Q1 2019 value amounting to $1.5 million.

  • Seres Therapeutics' Restructuring Costs changed N/A to $1.5 million in Q1 2019 from the same period last year, while for Dec 2019 it was $1.5 million, marking a year-over-year change of. This contributed to the annual value of $1.5 million for FY2019, which is N/A changed from last year.
  • Per Seres Therapeutics' latest filing, its Restructuring Costs stood at $1.5 million for Q1 2019.
  • In the past 5 years, Seres Therapeutics' Restructuring Costs ranged from a high of $1.5 million in Q1 2019 and a low of $1.5 million during Q1 2019